Last update 03 Jan 2025
Cediranib
Last update 03 Jan 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Cediranib (USAN/INN), Cediranib-maleate, Recentin + [4] |
Target |
Mechanism VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists), VEGFR3 antagonists(Vascular endothelial growth factor receptor 3 antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Login to view timeline
Structure
Molecular FormulaC25H27FN4O3 |
InChIKeyXXJWYDDUDKYVKI-UHFFFAOYSA-N |
CAS Registry288383-20-0 |
Related
111
Clinical Trials associated with CediranibA Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Overcoming PARP Inhibitor Resistance in BRCA Germline Mutation Positive Advanced Breast Cancer
WIndow of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in REnal Cell Cancer
100 Clinical Results associated with Cediranib
Login to view more data
100 Translational Medicine associated with Cediranib
Login to view more data
100 Patents (Medical) associated with Cediranib
Login to view more data
414
Literatures (Medical) associated with Cediranib20 Dec 2024JOURNAL OF CLINICAL ONCOLOGY
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Article
Author: Kohn, Elise C. ; Brady, Mark F. ; McDonald, Megan E. ; Duska, Linda R. ; Kavecansky, Juraj ; Moore, Richard G. ; Lheureux, Stephanie ; Rose, Peter G. ; McNally, Leah ; Provencher, Michèle ; Street, Daron ; Miller, Austin ; MacKay, Helen ; Wenzel, Lari B. ; Cantuaria, Guilherme ; Kim, Yong-Man ; Bookman, Michael A. ; Lee, Jung-Min ; Powell, Matthew ; Lea, Jayanthi ; Secord, Angeles Alvarez ; Huang, Helen Q. ; Leath, Charles A. ; Cadungog, Mark G.
PURPOSE:
We assessed the efficacy of cediranib, olaparib, and cediranib/olaparib compared with standard-of-care chemotherapy (SOC) in platinum-resistant or platinum-refractory epithelial ovarian cancer (PROC).
PATIENTS AND METHODS:
NRG-GY005 is an open-label, four-arm, phase II/III superiority trial enrolling patients with high-grade serous/endometrioid PROC and one to three previous therapies. Key exclusion criteria included previous receipt of poly(ADP-ribose) polymerase inhibitor or receipt of antiangiogenic therapy in the recurrent setting. Treatment arms (SOC [once weekly paclitaxel, topotecan, or pegylated liposomal doxorubicin], cediranib, olaparib, or cediranib/olaparib) were equally randomized. A preplanned interim futility analysis on the basis of progression-free survival (PFS) selected treatment arms to advance to phase III. PFS and overall survival (OS) were phase III coprimary end points, with hierarchical testing of PFS followed by OS to preserve type 1 error control, designed to have 90% power for a 0.625 PFS hazard ratio (HR). OS was tested after PFS in the multiple hierarchical testing procedure. Secondary end points included objective response rate (ORR) and patient-reported outcomes.
RESULTS:
Five hundred sixty-two eligible patients were enrolled for phase II/III. Three arms met PFS criteria to carry forward to phase III (SOC, cediranib/olaparib, and cediranib). Median PFS was 3.4, 5.2, and 4 months with SOC, cediranib/olaparib, and cediranib, respectively, with a median follow-up duration of 42.2 months. PFS HR estimates for cediranib/olaparib and cediranib (
v
SOC) were 0.796 (98.3% CI, 0.597 to 1.060) and 0.972 (98.3% CI, 0.726 to 1.300), respectively. Median OS was 13.6, 12.8, and 10.5 months, and of 443 patients with measurable disease, ORR was 8.6%, 24.7%, and 13.1% for SOC, cediranib/olaparib, and cediranib, respectively. No new safety signals were identified. In patients receiving cediranib/olaparib, no statistically significant difference was observed on the NFOSI-DRS-P subscale compared with SOC (98.3% CI, –1.3 to 1.5,
P
= .8725).
CONCLUSION:
The cediranib-containing arms demonstrated clinical activity on the basis of PFS but were not superior compared with SOC.
01 Nov 2024Clinical Lung Cancer
A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non–Small-Cell Lung Cancer
Article
Author: Camidge, D Ross ; Concannon, Kyle F ; Marotti, Marcelo ; Concannon, Kyle F. ; Glisson, Bonnie S. ; Camidge, D. Ross ; Doebele, Robert C. ; Camidge, D.Ross ; Heymach, John V. ; Doebele, Robert C ; Glisson, Bonnie S ; Heymach, John V ; Huang, Chao
INTRODUCTION:
Small cell lung cancer (SCLC) is known to express high levels of the proangiogenic factor vascular endothelial growth factor (VEGF). We assessed the safety and tolerability of cediranib, an oral inhibitor of VEGF receptor tyrosine kinases, in combination with etoposide and cisplatin as first-line therapy for extensive-stage (ES) SCLC or metastatic lung neuroendocrine cancer (NEC).
METHODS:
Patients received up to six 21-day cycles of etoposide (100 mg/m2, days 1-3) and cisplatin (80 mg/m2, day 1) with once-daily cediranib until disease progression or unacceptable toxicity. Cediranib dosing started at 30 mg with de-escalation cohorts planned based on cycle 1 dose-limiting toxicities (DLTs). An expansion cohort of 12 patients was enrolled at the recommended phase II dose.
RESULTS:
Twenty-two patients (18 with ES SCLC, 4 with NEC) received treatment. Only 4 patients were enrolled at the 30 mg cediranib dose before other studies established 20 mg/day as the recommended dose with chemotherapy. Among the 18 patients enrolled at the 20-mg dose, common adverse events included nausea/vomiting, neutropenia, and diarrhea; 8 patients (44%) had grade 1 or 2 hypertension, and 2 (11%) had grade 3 hemoptysis. For all 18 patients, the objective response rate and median progression-free survival duration were 67% and 7.9 months. Plasma levels of VEGF were significantly higher, and those of soluble VEGFR2 were significantly lower, on day 22 than at baseline but were not correlated with tumor shrinkage.
CONCLUSIONS:
Cediranib (20 mg) plus etoposide and cisplatin is well tolerated and has promising clinical activity.
01 Sep 2024Clinical Colorectal Cancer
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Article
Author: Siu, Lillian L ; Han, Ming ; Lam, Bernard ; Ayodele, Olubukola ; Hernando-Calvo, Alberto ; Avery, Lisa ; Berman, Hal K ; Pugh, Trevor J ; Stayner, Lee-Anne ; Bruce, Jeffrey P ; Hansen, Aaron R ; Salawu, Abdulazeez ; Wang, Ben X ; Razak, Albiruni R A ; Vila-Casadesús, Maria ; Lungu, Ilinca ; Abbas-Aghababazadeh, Farnoosh ; Spreafico, Anna ; Yang, S Y Cindy ; Vivancos, Ana ; Bedard, Philippe L ; Haibe-Kains, Benjamin ; Sanz-Garcia, Enrique
BACKGROUND:
The use of immunotherapy in mismatch repair proficient colorectal cancer (pMMR-CRC) or pancreatic adenocarcinoma (PDAC) is associated with limited efficacy. DAPPER (NCT03851614) is a phase 2, basket study randomizing patients with pMMR CRC or PDAC to durvalumab with olaparib (durvalumab + olaparib) or durvalumab with cediranib (durvalumab + cediranib).
METHODS:
PDAC or pMMR-CRC patients were randomized to either durvalumab+olaparib (arm A), or durvalumab + cediranib (arm B). Co-primary endpoints included pharmacodynamic immune changes in the tumor microenvironment (TME) and safety. Objective response rate, progression-free survival (PFS) and overall survival (OS) were determined. Paired tumor samples were analyzed by multiplexed immunohistochemistry and RNA-sequencing.
RESULTS:
A total of 31 metastatic pMMR-CRC patients were randomized to arm A (n = 16) or B (n = 15). In 28 evaluable patients, 3 patients had stable disease (SD) (2 patients treated with durvalumab + olaparib and 1 patient treated with durvalumab + cediranib) while 25 had progressive disease (PD). Among patients with PDAC (n = 19), 9 patients were randomized to arm A and 10 patients were randomized to arm B. In 18 evaluable patients, 1 patient had a partial response (unconfirmed) with durvalumab + cediranib, 1 patient had SD with durvalumab + olaparib while 16 had PD. Safety profile was manageable and no grade 4-5 treatment-related adverse events were observed in either arm A or B. No significant changes were observed for CD3+/CD8+ immune infiltration in on-treatment biopsies as compared to baseline for pMMR-CRC and PDAC independent of treatment arms. Increased tumor-infiltrating lymphocytes at baseline, low baseline CD68+ cells and different immune gene expression signatures at baseline were associated with outcomes.
CONCLUSIONS:
In patients with pMMR-CRC or PDAC, durvalumab + olaparib and durvalumab + cediranib showed limited antitumor activity. Different immune components of the TME were associated with treatment outcomes.
100 Deals associated with Cediranib
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Ovarian Cancer | NDA/BLA | - | - | |
| Ovarian Serous Adenocarcinoma | Phase 3 | US | 03 May 2016 | |
| Ovarian Serous Adenocarcinoma | Phase 3 | JP | 03 May 2016 | |
| Ovarian Serous Adenocarcinoma | Phase 3 | CA | 03 May 2016 | |
| Ovarian Serous Adenocarcinoma | Phase 3 | PR | 03 May 2016 | |
| Ovarian Serous Adenocarcinoma | Phase 3 | KR | 03 May 2016 | |
| Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | US | 03 May 2016 | |
| Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | JP | 03 May 2016 | |
| Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | CA | 03 May 2016 | |
| Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | PR | 03 May 2016 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2/3 | Platinum-Resistant Ovarian Carcinoma high-grade serous | endometrioid | - | lntptcwjtp(swcvtsnbsd) = kiadxpyiqh fvysgbqiwl (ljozjwjspr ) View more | Negative | 20 Dec 2024 | ||
lntptcwjtp(swcvtsnbsd) = lvenxewvjb fvysgbqiwl (ljozjwjspr ) View more | |||||||
Phase 2 | 34 | AZD2171 (Cediranib) (AZD2171 (Cediranib) 30 mg) | zixmmpcqbs(yvpfylnktq) = nplkilboeh weeaevqxud (jysqbczmsk, jaalwspiwj - fxlygipnls) View more | - | 19 Sep 2024 | ||
AZD2171 (Cediranib)+Sunitinib Malate (AZD2171 (Cediranib) 30 mg Followed by Sunitinib Malate 37.5 mg) | zixmmpcqbs(yvpfylnktq) = ctwgogjjmc weeaevqxud (jysqbczmsk, nkxetgkqaz - tpcoberbzl) View more | ||||||
Phase 2 | 124 | mbqlhbxgwd(njxkqlrmgn) = xoxixcknvr xhbnjyizqc (wnfqngslen ) View more | - | 10 Mar 2024 | |||
mbqlhbxgwd(njxkqlrmgn) = bgttnoopam xhbnjyizqc (wnfqngslen ) View more | |||||||
Phase 2 | 70 | lnfjjqsuyh(csvjqvcsnn) = rsgafvfolw dorjddldfl (nsqajpvuki, ibjbjvcwwj - xiukbitvct) View more | - | 02 Feb 2024 | |||
(Arm B (Bevacizumab)) | lnfjjqsuyh(csvjqvcsnn) = vyexjkezlw dorjddldfl (nsqajpvuki, jqnaasbobx - qwgsxiaiyx) View more | ||||||
Phase 3 | 565 | (Standard of care (SOC)) | yeccljspzc(rjicsaifkl) = nltrjeeuhg lljszswvnr (ylzfehnvbt ) | Negative | 22 Oct 2023 | ||
Olaparib (O) | yeccljspzc(rjicsaifkl) = kiibnxhoba lljszswvnr (ylzfehnvbt ) | ||||||
Phase 2 | 97 | overall | qzwwwejgys(wlwxwvfsso) = cdoqvnjsmv wgfxqgsxdj (ioposkgqwz ) | Negative | 31 May 2023 | ||
qzwwwejgys(wlwxwvfsso) = qakuxuwuxj wgfxqgsxdj (ioposkgqwz ) View more | |||||||
Phase 2 | - | wdeykmaoke(bbdjyobcql) = hrzbspacdg zlhgfcfhix (rkuzpqflra, 10.7 - NR) View more | - | 31 May 2023 | |||
Phase 2 | Metastatic endometrial cancer Maintenance | - | mmlhmlmpyl(wgcjryvkll) = ecllbcsfpa xfbxudljej (ewffawnywd ) | - | 31 May 2023 | ||
Phase 2 | 70 | Cediranib/Olaparib | pvtctenkos(sgzixddgjs) = dfwbxcpfrm wgtwcolvgj (bfzrycunzk ) View more | Negative | 14 Nov 2022 | ||
Bevacizumab | pvtctenkos(sgzixddgjs) = dpuxvhasug wgtwcolvgj (bfzrycunzk ) View more | ||||||
Phase 2 | 30 | lqtmmviqqv(cbgvkepcim) = Three participants had grade 3+ SAEs causally related to cediranib+/-olaparib (one diarrhoea; one diarrhoea and TIA; one vomiting) dhqxlvfxbx (zauppssqmq ) | Negative | 20 Oct 2022 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free